The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: Justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 9, 2009, Pages 2352-2365

  O'Mara, Tracy A ^a,b   Clements, Judith A ^a   Spurdle, Amanda B ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL INVASION; CELL PROLIFERATION; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENETIC MARKER; HUMAN; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349324683     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1184     Document Type: Review

References (136)

1. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008;40:1362-1378
2. Salamonsen LA, Zhang J, Hampton A, Lathbury L. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 2000;15 Suppl 3:112-119
3. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-1517 (Pubitemid 26301653)
4. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-751
5. Kronenberg F. Genome-wide association studies in aging-related processes such as diabetes mellitus, atherosclerosis and cancer. Exp Gerontol 2008;43:39-43. (Pubitemid 350235151)
6. Altshuler D, Daly M. Guilt beyond a reasonable doubt. Nat Genet 2007;39:813-815
7. Tantoso E, Yang Y, Li KB. How well do HapMap SNPs capture the untyped SNPs? BMC Genomics 2006;7:238.
8. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995;270:14313-14318
9. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-2072
10. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68 (Pubitemid 10098769)
11. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006;231:20-27 (Pubitemid 43063974)
12. Sood AK, Fletcher MS, Coffin JE, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004;190:899-909. (Pubitemid 38561505)
13. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-313 (Pubitemid 40222426)
14. Imada K, Ito A, Sato T, Namiki M, Nagase H, Mori Y. Hormonal regulation of matrix metalloproteinase 9/gelatinase B gene expression in rabbit uterine cervical fibroblasts. Biol Reprod 1997;56:575-580 (Pubitemid 27084090)
15. Bratland A, Ragnhildstveit E, Bjornland K, et al. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clin Exp Metastasis 2003;20:541-547 (Pubitemid 37297182)
16. Silverberg S. Tumours of the uterine corpus. In: Tavassoli F, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003, p. 217-258
17. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17
18. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-268 (Pubitemid 24301898)
19. Tabibzadeh S. The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Mol Hum Reprod 1996;2:77-92. (Pubitemid 126715854)
20. Takemura M, Azuma C, Kimura T, et al. Malignant cell-specific gelatinase activity in human endometrial carcinoma. Cancer 1992;70:147-151
21. Guo W, Chen G, Zhu C, Wang H. [Expression of matrix metalloproteinase- 2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2002;37:604-607
22. Karahan N, Guney M, Baspinar S, Oral B, Kapucuoglu N, Mungan T. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 2007;28:184-188 (Pubitemid 46985638)
23. Honkavuori M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol 2007;104:217-221 (Pubitemid 46054133)
24. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res 2005;25:4101-4105 (Pubitemid 41665191)
25. Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Darai E. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer 2006;16:1911-1917 (Pubitemid 44470055)
26. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase- 1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 2006;17:637-645
27. Aglund K, Rauvala M, Puistola U, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004;94:699-704. (Pubitemid 39194463)
28. Di Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002;94:1466-1475 (Pubitemid 34213290)
29. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.
30. Misugi F, Sumi T, Okamoto E, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med 2005;16:541-546
31. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999;84:470-477
32. Bogusiewicz M, Stryjecka-Zimmer M, Rechberger T. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer - a preliminary study]. Ginekol Pol 2007;78:366-372
33. Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997;28:220-226 (Pubitemid 27069190)
34. Laird SM, Dalton CF, Okon MA, Bunning RA, Marshall R, Li TC. Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma. J Reprod Fertil 1999;115:225-232 (Pubitemid 29168114)
35. Yang X, Dong Y, Zhao J, et al. Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract 2007;203:499-505. (Pubitemid 47065354)
36. Sato H, Takino T, Miyamori H. Roles of membrane-type matrix metalloproteinase- 1 in tumor invasion and metastasis. Cancer Sci 2005;96:212-217 (Pubitemid 40767057)
37. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003;94:569-574 (Pubitemid 36975009)
38. Mutter GL, Baak JP, Fitzgerald JT, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001;83:177-185
39. Tunuguntla R, Ripley D, Sang QX, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89:453-459 (Pubitemid 36687792)
40. Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 2003;97:79-89. (Pubitemid 36033866)
41. Monaghan H, MacWhinnie N, Williams AR. The role of matrix metalloproteinases- 2, -7 and -9 and β-catenin in high grade endometrial carcinoma. Histopathology 2007;50:348-357
42. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in non-endometrioid carcinomas. Cancer Res 2003;63:5697-5702 (Pubitemid 37187463)
43. Sugiyama Y, Dan S, Yoshida Y, et al. A large-scale gene expression comparison of microdissected, small-sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue. Clin Cancer Res 2003;9:5589-5600 (Pubitemid 37499479)
44. Pilka R, Domanski H, Hansson S, Eriksson P, Casslen B. Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26. Mol Hum Reprod 2004;10:641-650
45. Ueda K, Yamada K, Urashima M, et al. Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol Rep 2007;17:731-735
46. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004;92:719-725 (Pubitemid 38183172)
47. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008;1:re6.
48. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5325 (Pubitemid 28551108)
49. Nishioka Y, Kobayashi K, Sagae S, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 2000;91:612-615 (Pubitemid 30453788)
50. Sugimoto M, Yoshida S, Kennedy S, Deguchi M, Ohara N, Maruo T. Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig 2006;13:523-529 (Pubitemid 44528299)
51. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994;70:506-512 (Pubitemid 24268556)
52. Cardillo MR, Di Silverio F, Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 2006;26:973-982
53. Riddick AC, Shukla CJ, Pennington CJ, et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005;92:2171-2180
54. Lichtinghagen R, Musholt PB, Stephan C, et al. mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. Anticancer Res 2003;23:2617-2624 (Pubitemid 36897135)
55. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005;33:44-50. (Pubitemid 40487192)
56. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511-8515 (Pubitemid 37549509)
57. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004;7:327-332 (Pubitemid 41721791)
58. Sauer CG, Kappeler A, Spath M, et al. Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 2004;444:518-526 (Pubitemid 38858375)
59. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Jr., Kallakury BV. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198-205. (Pubitemid 36337424)
60. Mylona E, Nomikos A, Magkou C, et al. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 2007;50:338-347 (Pubitemid 46169418)
61. Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol 2007;96:46-53. (Pubitemid 47015448)
62. Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001;173:79-82. (Pubitemid 32907512)
63. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004;10:1057-1063 (Pubitemid 38198907)
64. Liu SC, Yang SF, Yeh KT, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006;371:92-96 (Pubitemid 44162898)
65. Przybylowska K, Kluczna A, Zadrozny M, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006;95:65-72. (Pubitemid 43228082)
66. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008;122:2050-2056
67. Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol 2006;37:1316-1323 (Pubitemid 44380276)
68. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90:1414-1421 (Pubitemid 38586271)
69. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 2007;53:1280-1288
70. Kuvaja P, Wurtz SO, Talvensaari-Mattila A, Brunner N, Paakko P, Turpeenniemi-Hujanen T. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study. Cancer Biomark 2007;3:293-300.
71. Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics 2008;7:424-430 (Pubitemid 351298453)
72. Sillanpaa SM, Anttila MA, Voutilainen KA, et al. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin expression. Int J Cancer 2006;119:1792-1799 (Pubitemid 44356835)
73. Mylona E, Kapranou A, Mavrommatis J, Markaki S, Keramopoulos A, Nakopoulou L. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer. APMIS 2005;113:246-255 (Pubitemid 40676805)
74. Hashimoto K, Kihira Y, Matuo Y, Usui T. Expression of matrix metalloproteinase- 7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998;160:1872-1876 (Pubitemid 128746778)
75. Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006;10:499-510. (Pubitemid 44872701)
76. Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403-1411
77. Jiang WG, Davies G, Martin TA, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006;17:583-590
78. Kasper G, Reule M, Tschirschmann M, et al. Stromelysin-3 overexpression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway. BMC Cancer 2007;7:12. (Pubitemid 46242722)
79. Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 2005;65:11101-11108
80. Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006;236:292-301.
81. Wu MF, Liao GN, Jia P, Xi L, Lu YP, Ma D. [Inhibitory effect of MT1- MMP antisense nucleotide on invasion of human highly metastatic ovarian cancer cell line SW626]. Ai Zheng 2004;23:1263-1266
82. Cao J, Chiarelli C, Kozarekar P, Adler HL. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb Haemost 2005;93:770-778 (Pubitemid 40485416)
83. Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993;53:417-422 (Pubitemid 23031858)
84. Zhang YG, Du J, Tian XX, Zhong YF, Fang WG. Expression of E-cadherin, β-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J (Engl) 2007;120:1597-1605 (Pubitemid 47595752)
85. Jinga D, Stefanescu M, Blidaru A, Condrea I, Pistol G, Matache C. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors. Roum Arch Microbiol Immunol 2004;63:141-158
86. Kanamori Y, Matsushima M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999;59:4225-4227 (Pubitemid 29418732)
87. Hughes S, Agbaje O, Bowen RL, et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 2007;13:6673-6680 (Pubitemid 350206803)
88. Six L, Grimm C, Leodolter S, et al. A polymorphism in the matrix metalloproteinase- 1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol 2006;100:506-510 (Pubitemid 43246866)
89. Przybylowska K, Zielinska J, Zadrozny M, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 2004;23:121-125 (Pubitemid 38552606)
90. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-7558 (Pubitemid 37392068)
91. Zhou Y, Yu C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase- 2 genes. Carcinogenesis 2004;25:399-404. (Pubitemid 38344407)
92. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 2008;65:68-72.
93. Lei H, Hemminki K, Altieri A, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007;103:61-69 (Pubitemid 46653260)
94. Li XL, Kang S, Zhao XW, et al. [Association of SNPs in the promoter of MMP-2 and TIMP-2 genes with epithelial ovarian cancer]. Yi Chuan 2008;30:455-462
95. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004;88:197-204. (Pubitemid 40137297)
96. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055-13060 (Pubitemid 26175880)
97. Ghilardi G, Biondi ML, Caputo M, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 2002;8:3820-3823 (Pubitemid 35424775)
98. Szyllo K, Smolarz B, Romanowicz-Makowska H, Niewiadomski M, Kozlowska E, Kulig A. The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J Exp Clin Cancer Res 2002;21:357-361
99. Li Y, Jin X, Kang S, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol 2006;101:92-96 (Pubitemid 43303565)
100. Lei H, Zaloudik J, Vorechovsky I. Lack of association of the -1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem 2002;48:798-799 (Pubitemid 34439124)
101. Smolarz B, Szyllo K, Romanowicz-Makowska H, Niewiadomski M, Kozlowska E, Kulig A. PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol 2003;54:233-238 (Pubitemid 38233127)
102. Krippl P, Langsenlehner U, Renner W, et al. The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res 2004;10:3518-3520 (Pubitemid 38685461)
103. Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001;21:1834-1839 (Pubitemid 34219789)
104. Beeghly-Fadiel A, Long JR, Gao YT, et al. Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res 2008;68:6453-6459
105. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-1794 (Pubitemid 29181405)
106. Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L. TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet 2007;172:38-44. (Pubitemid 44920266)
107. Shin A, Cai Q, Shu XO, Gao YT, Zheng W. Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 2005;7:R506-12.
108. Decock J, Long JR, Laxton RC, et al. Association of matrix metalloproteinase- 8 gene variation with breast cancer prognosis. Cancer Res 2007;67:10214-10221 (Pubitemid 350070794)
109. Stadlmann S, Pollheimer J, Moser PL, et al. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur J Cancer 2003;39:2499-2505 (Pubitemid 37340163)
110. Zhang B, Cao X, Liu Y, et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008;8:83. (Pubitemid 351622376)
111. DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994;30A:2170-2180
112. Shagisultanova EI, Novikova IA, Sidorenko YS, Marchenko GN, Strongin AY, Malkhosyan SR. The matrix metalloproteinase-21 gene 572C/Tpolymorphism and the risk of breast cancer. Anticancer Res 2004;24:199-201. (Pubitemid 38279708)
113. Wenham RM, Calingaert B, Ali S, et al. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig 2003;10:381-387 (Pubitemid 37102848)
114. Albayrak S, Canguven O, Goktas C, Aydemir H, Koksal V. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol Int 2007;79:312-315 (Pubitemid 350136516)
115. Maatta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 2007;27:2753-2758 (Pubitemid 47227993)
116. Ripley D, Tunuguntla R, Susi L, Chegini N. Expression of matrix metalloproteinase- 26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma. Int J Gynecol Cancer 2006;16:1794-1800 (Pubitemid 44470038)
117. Hantke B, Harbeck N, Schmalfeldt B, et al. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. Biol Chem 2003;384:1247-1251 (Pubitemid 37121196)
118. Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H, Hofler H. Stromelysin- 3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch 2000;437:618-624 (Pubitemid 32003092)
119. Tanimoto H, Underwood LJ, Shigemasa K, et al. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999;20:88-98. (Pubitemid 29130694)
120. Kamat AA, Fletcher M, Gruman LM, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006;12:1707-1714
121. Stenman M, Paju A, Hanemaaijer R, et al. Collagenases (MMP-1, -8 and -13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts. Tumour Biol 2003;24:9-12. (Pubitemid 36578813)
122. Mylona E, Magkou C, Giannopoulou I, et al. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res 2006;8:R57. (Pubitemid 44698286)
123. Chabottaux V, Sounni NE, Pennington CJ, et al. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res 2006;66:5165-5172 (Pubitemid 43844939)
124. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-2060
125. Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006;47:333-342
126. Tetu B, Brisson J, Wang CS, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res; 20068:R28.
127. Yao GY, Yang MT, Rong TH, He P. [Significance of membrane type-1 matrix metalloproteinase expression in breast cancer]. Ai Zheng 2004;23:1482-1486
128. Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, Lopez-Otin C. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 2000;291:137-155 (Pubitemid 30089761)
129. Nakopoulou L, Panayotopoulou EG, Giannopoulou I, et al. Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients' outcome. Mod Pathol 2002;15:1154-1161 (Pubitemid 35435133)
130. Ahmad A, Hanby A, Dublin E, et al. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 1998;152:721-728 (Pubitemid 28110719)
131. Chenard MP, O'Siorain L, Shering S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69:448-451 (Pubitemid 27050520)
132. Engel G, Heselmeyer K, Auer G, Backdahl M, Eriksson E, Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 1994;58:830-835 (Pubitemid 24306372)
133. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 1996;73:1401-1408 (Pubitemid 126425209)
134. Tetu B, Brisson J, Lapointe H, Bernard P. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 1998;29:979-985 (Pubitemid 28422047)
135. Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997;74:220-223 (Pubitemid 27234514)
136. Lein M, Nowak L, Jung K, et al. Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. Ann N Y Acad Sci 1999;878:544-546 (Pubitemid 29353608)